Role of DNA Repair Gene Polymorphisms in the Efficiency of Platinum-Based Adjuvant Chemotherapy for Non-Small Cell Lung Cancer

被引:0
|
作者
Mathiaux, Juliette [1 ,2 ]
Le Morvan, Valerie [1 ]
Pulido, Marina [3 ,4 ]
Jougon, Jacques [2 ]
Begueret, Hugues [2 ]
Robert, Jacques [1 ]
机构
[1] Univ Bordeaux, Inst Bergonie, INSERM, U916, F-33076 Bordeaux, France
[2] Hop Haut Leveque, Ctr Hosp Univ Bordeaux, Bordeaux, France
[3] INSERM Ctr Invest Clin CIC EC7, Bordeaux, France
[4] Inst Bergonie, Unite Rech & Epidemiol Clin, Bordeaux, France
关键词
VINORELBINE PLUS CISPLATIN; COMBINATION CHEMOTHERAPY; PHASE-III; ERCC1; SURVIVAL; EXPRESSION; TOXICITY; ASSOCIATION; GEMCITABINE; CARCINOMAS;
D O I
10.1007/BF03256406
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Cisplatin-based adjuvant treatment of non-small cell lung cancer (NSCLC) has become standard, thanks to the studies that have shown a significant survival advantage. The identification of patients who could benefit from this adjuvant treatment would allow ineffective and toxic administrations to be avoided. Immunohistochemical expression of the excision repair cross-complementation group (ERCC)-1 protein has been associated with response to platinum-based chemotherapy in patients with NSCLC, and some polymorphisms of the genes involved in DNA repair have been shown to be associated with survival in advanced NSCLC. Objective: The aim of our study was to evaluate the progression-free survival and tolerability of adjuvant treatment with platinum-based chemotherapy in patients with NSCLC, according to common DNA repair gene polymorphisms and ERCC1 expression. Methods: We investigated the association of three DNA repair gene polymorphisms - Asn118Asn in ERCC1 (rs11615), Lys751Gln in ERCC2 (rs13181), and Asp1104His in ERCC5 (rs17655) - with the progression-free survival of 85 patients treated with platinum-based chemotherapy after surgery for NSCLC. Results: We did not find significant associations between any of these polymorphisms and progression-free survival, nor did we observe any difference in progression-free survival according to ERCC1 expression. Conclusion: The previously reported impact of DNA repair gene polymorphisms on platinum-based chemotherapy treatment of advanced NSCLC was not observed in our study in the adjuvant setting.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 50 条
  • [1] Role of DNA Repair Gene Polymorphisms in the Efficiency of Platinum-Based Adjuvant Chemotherapy for Non-Small Cell Lung Cancer
    Juliette Mathiaux
    Valérie Le Morvan
    Marina Pulido
    Jacques Jougon
    Hugues Bégueret
    Jacques Robert
    [J]. Molecular Diagnosis & Therapy, 2011, 15 : 159 - 166
  • [2] Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients
    Jun-Yan Liu
    Chen-Yue Qian
    Yuan-Feng Gao
    Juan Chen
    Hong-Hao Zhou
    Ji-Ye Yin
    [J]. 癌症, 2017, 36 (06) : 267 - 273
  • [3] Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients
    Liu, Jun-Yan
    Qian, Chen-Yue
    Gao, Yuan-Feng
    Chen, Juan
    Zhou, Hong-Hao
    Yin, Ji-Ye
    [J]. CHINESE JOURNAL OF CANCER, 2017, 36
  • [4] Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients
    Perez-Ramirez, Cristina
    Canadas-Garre, Marisa
    Alnatsha, Ahmed
    Villar, Eduardo
    Valdivia-Bautista, Javier
    Jose Faus-Dader, Maria
    Angel Calleja-Hernandez, Miguel
    [J]. PHARMACOGENOMICS JOURNAL, 2019, 19 (02): : 164 - 177
  • [5] Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients
    Cristina Pérez-Ramírez
    Marisa Cañadas-Garre
    Ahmed Alnatsha
    Eduardo Villar
    Javier Valdivia-Bautista
    María José Faus-Dáder
    Miguel Ángel Calleja-Hernández
    [J]. The Pharmacogenomics Journal, 2019, 19 : 164 - 177
  • [6] Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy
    Butkiewicz, Dorota
    Drosik, Anna
    Suwinski, Rafal
    Krzesniak, Malgorzata
    Rusin, Marek
    Kosarewicz, Agata
    Rachtan, Jadwiga
    Matuszczyk, Iwona
    Gawkowska-Suwinska, Marzena
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (07) : E1100 - E1108
  • [7] Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems
    Xiong, Yi
    Huang, Bi-Yun
    Yin, Ji-Ye
    [J]. MEDICAL ONCOLOGY, 2017, 34 (04)
  • [8] Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems
    Yi Xiong
    Bi-Yun Huang
    Ji-Ye Yin
    [J]. Medical Oncology, 2017, 34
  • [9] Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy
    Zhang, L.
    Ma, W.
    Li, Y.
    Wu, J.
    Shi, G. Y.
    [J]. GENETICS AND MOLECULAR RESEARCH, 2014, 13 (01) : 228 - 236
  • [10] Association of DNA Repair Gene Polymorphisms With Response to Platinum-Based Doublet Chemotherapy in Patients With Non-Small-Cell Lung Cancer
    Shiraishi, Kouya
    Kohno, Takashi
    Tanai, Chiharu
    Goto, Yasushi
    Kuchiba, Aya
    Yamamoto, Seiichiro
    Tsuta, Koji
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Sekine, Ikuo
    Ohe, Yuichiro
    Tamura, Tomohide
    Yokota, Jun
    Kunitoh, Hideo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (33) : 4945 - 4952